CRESCENT BIOPHARMA, INC. — Form 4
Filed July 20, 2026 · analyzed by the Insider Agent
4
▲ Likely positive
significance 78/100
What the filing says
Director Fairmount Funds Management LLC (CBIO) bought 1.4M shares (~$20.0M) on the open market (38% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.